Effects of the Dual Sodium-Glucose Linked Transporter Inhibitor, Licogliflozin Versus Placebo or Empagliflozin in Patients With Type 2 Diabetes and Heart Failure

British Journal of Clinical Pharmacology - United Kingdom
doi 10.1111/bcp.14248
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Wiley

Related search

Empagliflozin: A New Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Drugs in Context
Molecular MedicinePharmacology
2014English

Retrospective Analysis of Effects of Sodium-Glucose Co-Transporter 2 Inhibitor in Japanese Type 2 Diabetes Mellitus Patients With Chronic Kidney Disease

Diabetes and Vascular Disease Research
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2018English

Clinical Considerations When Introducing Sodium-Glucose Co-Transporter 2 Inhibition in Patients With Heart Failure

Circulation Reports
2020English

Effects of Sodium Glucose Cotransporter Type 2 Inhibitors on Heart Failure

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Euglycemic Diabetic Ketoacidosis Induced by Empagliflozin, Sodium-Glucose Cotransporter-2 Inhibitor, in Patient With Diabetes Mellitus Type 2 After Thoracic Surgery

Lijecnicki Vjesnik
Medicine
2020English

Early Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Type 2 Diabetes: Study Based on Continuous Glucose Monitoring

Diabetology and Metabolic Syndrome
Internal MedicineEndocrinologyMetabolismDiabetes
2017English

Evaluation of the Effects of Sodium–glucose Co‐transporter 2 Inhibition With Empagliflozin on Morbidity and Mortality in Patients With Chronic Heart Failure and a Preserved Ejection Fraction: Rationale for and Design of the EMPEROR‐Preserved Trial

European Journal of Heart Failure
Cardiovascular MedicineCardiology
2019English

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally

US Endocrinology
EndocrinologyMetabolismDiabetes
2017English

Heart Failure Prevention With Sodium‐glucose Cotransporter 2 Inhibitors

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy